A commercially-suitable tricholine nasal formulation for administration to a human as a nasal spray is disclosed. The tricholine nasal formulation includes an aqueous solution of tricholine citrate, a volatile oil and a buffer system. The disclosed tricholine nasal formulation possesses an acceptable odor and a reasonable shelf-life. The tricholine nasal formulation may be used to treat the symptoms associated with stress, anxiety, depression, malaise, or “burn out” syndrome. Optionally, a moisturizer is included in the composition to alleviate any dryness resulting from administration of the formulation to a user. A preservative may be included in the composition to produce a longer shelf-life.
